2020: Severe Malaria Treatment

On This Day in Health: May 26, 2020

On May 26, 2020, the U.S. Food and Drug Administration approved intravenous artesunate for the initial treatment of severe malaria in adults and children. The decision gave the United States an approved medicine for an urgent condition after the discontinuation of intravenous quinidine had left a treatment gap. Artesunate had already been available through an expanded-access program, so the date did not mark its discovery or its first use anywhere in the world. It marked a specific regulatory step toward a more established supply of an important hospital treatment. That distinction connects the scientific achievement with the practical question of access when a patient becomes critically ill.

Malaria is caused by parasites transmitted through the bites of infected mosquitoes. Severe disease can damage vital organs and requires prompt clinical treatment. Artesunate acts against the parasite, and intravenous delivery provides a way to begin treatment when serious illness makes an oral approach unsuitable. The approval covered initial treatment rather than a complete course by itself. Patients still needed an appropriate full oral antimalarial regimen afterward. This sequence matters because rapid control of a dangerous illness and completion of parasite treatment are connected responsibilities. A new approved injectable medicine could improve the first response while leaving the rest of the care pathway essential.

The evidence included large randomized trials conducted in Asia and Africa, comparing injectable artesunate with quinine in severe malaria. The FDA described lower in-hospital mortality in the artesunate groups. Those studies were important because they assessed survival in the setting where the medicine was needed, rather than relying only on a laboratory measure of parasite activity. The patients who participated helped establish evidence that could inform treatment far beyond the individual hospitals involved. Approval nevertheless did not mean that every severely ill person would recover. Clinical teams still had to diagnose the infection, manage complications and monitor the response to treatment while arranging the necessary follow-on medicine.

The anniversary highlights a part of medical progress that can be less visible than a new discovery: making an evidence-supported treatment available through a dependable regulatory and commercial route. A medicine can already be known to specialists yet remain difficult to obtain quickly when an emergency occurs. The May 26 decision addressed that problem in a defined national setting. Its significance rests on both the trial evidence and the work required to turn that evidence into bedside access. Remembering the date means recognizing the international research behind artesunate, the seriousness of severe malaria and the importance of completing care after the immediate crisis begins to improve.